

INFOBulletin

Keeping health care providers informed of payment, policy or program changes

To: Prescribers with the Authority to Prescribe Controlled Drugs

Published By: Ontario Public Drug Programs

Date Issued: February 17, 2012 **Bulletin #:** 4557

Re: Important Notice Regarding Change in Funding Status of Oxycodone Controlled Release Tablet – (Discontinuation of OxyContin and introduction of OxyNEO)

Effective March 1, 2012 Purdue Pharma is withdrawing its current formulation of oxycodone controlled release tablet, OxyContin, and introducing OxyNEO.

The purpose of this INFOBulletin is to inform you of the changes that the Ministry of Health and Long-Term Care (the ministry) will implement as a result of the introduction of OxyNEO. These changes are based on extensive discussions with practicing pain specialists, addiction experts and other health care providers, and are designed to balance appropriate use, patient care and the growing problem of opioid addiction in Ontario.

We have developed a list of questions and answers (attached) to facilitate an understanding of this change. We encourage you to read this material in its entirety, as it sets out important information that relates to a number of Ontario Drug Benefit (ODB) Formulary listing changes for oxycodone controlled release tablets that will come into effect on **February 29, 2012**.